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College of St. Scholastica, Duluth, Minnesota

Purpose Statement
The aim of this project was reducing CRBSI’s below
the predicted number of bloodstream infections with
the implementation of the ClearGuard® chlorhexidinebased antimicrobial disinfecting cap.

Synthesis of Evidence
Two large clustered-randomized trials have proven
that ClearGuard® caps can reduce CRBSI by 56-69%
(Hymes et al., 2017; Brunelli et al., 2018).
In the 13 months of the
My DNP Project
Brunelli et al., (2018)
study, BSI rates
1 clinic
decreased significantly
3
months
with the use of the
54
patients
ClearGurad® caps
(0.28 versus 0.75 PBCs
per 1000 CVC-days respectively; P=0.001)
Using the ClearGuard® caps were associate with
a 56% decreased rate of BSI when compared to
the use of standard caps. During the last 6 months
of the study, use of the ClearGuard® caps were
associated with a 69% lower BSI (Hymes et al.,
2017). SUSTAINED USE = BETTER OUTCOMES
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Evidence-Based Practice Change
Pre/Post Measures
Pre-implementation audits (prior 3 months)
206 patients, 49 patients with a tunneled
catheter and 2 access related BSI’s.
1 BSI was attributed to a fistula,
And 1 BSI was attributed to a graft.
0 BSI’s were attributed to a catheter.
Post-implementation audits (my project-3 months)
186 patients, 54 patients with a tunneled
catheter.
0 BSI’s were attributed to a fistula, graft,
or catheter during this time period
(Table 2).
Results were not unexpected….EXTENDED use of the ClearGuard® cap proves
to decrease CRBSI by 56-69% The Hymes (2017) study showed the last 6
months of use: infection rates of 0.18 (3rd qtr.) and 0.26/1000 CVC days (4th qtr.)
compared to the first six months at 0.33/1000 days for both the 1st and
2nd quarter. Limitations encountered were time and a small sample size. A threemonth time frame did not allow enough time to adequately assess for
improvement of CRBSI’s and using one single hemodialysis unit and not all 12
outpatient units associated with this organization was also another limitation.
Using more dialysis units would have given a much larger sample size.
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Currently use: Tego® connector.
Research of a 70% isopropyl
disinfecting cap placed over the
Tego® connector not as superior
compared to the ClearGuard®
cap
ClearGuard® cap uses a dry form of
chlorhexidine antimicrobial disinfectant. The
cap is placed on the ends of the hemodialysis
catheter at the end of each treatment and
remains in place between treatments to provide
continuous disinfection.
ClearGuard® caps can reduce CRBSI by 56-69%

After completion of my project, based on all data
available, the senior organization of this project
unit decided to implement the ClearGuard® cap
throughout their entire hemodialysis population
This includes12 hemodialysis units, totaling 405
patients, with 119 catheters within their
organization.
Reduction of CRBSI will have beneficial impacts on healthcare organizations and this patient population

